ClinicalTrials.gg
CompletedNCT04470726NMSCUpdated Nov 4, 2026

Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype

A Phase 1 interventional study of AIV001 and AIV001 suspension in Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma and Nonmelanoma Skin Cancers, sponsored by AiViva BioPharma, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by AiViva BioPharma, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Jun 2023, 3 years 5 months ago, and no results have been posted to the registry.
Updated Nov 4, 2026Design changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 171 studies in Carcinoma, Basal Cell with a site in United States — 23 open to participants now, 38 under way, 2 of them phase 3. Carcinoma, Basal Cell · United States.

Enrollment
93rd of 139
26 · median 40
Started
2020
with 7 others
Phase 1
36 of 171
4 open now
Registered
116th of 171
by date

Among the 171 studies in Carcinoma, Basal Cell with a site in United States, this one is the 93rd largest by enrollment of the 139 interventional ones that give a count, is one of 8 that started in 2020, is one of 36 in phase 1, and was the 116th registered.

Carcinoma, Basal Cell

389 studies on the registry are indexed under Carcinoma, Basal Cell; 69 are open to participants now.

Browse Carcinoma, Basal Cell studies →

Open to participants now

23 of the 171 studies in Carcinoma, Basal Cell with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Carcinoma, Basal Cell studies recruiting now, 49 (92%) set no upper age limit and none (0%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Carcinoma, Basal Cell with a site in United States, or all of them as a file.
02

Study summary

To evaluate safety and efficacy of AIV001 treatment on low-risk Nonmelanoma Skin Caner of the basal cell carcinoma subtype.

Read the detailed description

AIV001 (axitinib) has been formulated to provide focal disease-modifying therapy for patients with nonmelanoma skin cancer (NMSC) of the basal cell carcinoma (BCC) subtype. AIV001 targets angiogenesis, inflammation, and fibrosis associated with various pathological skin conditions and was formulated as a simple intradermal/intratumoral injection demonstrating prolonged skin residence. Surgical excision is the standard treatment for NMSC of the basal cell carcinoma subtype for lesions of \< 20 mm. Surgical removal of lesions is effective but for some patients unwilling or contraindicated for surgery a nonsurgical option is needed. A nonsurgical option will eliminate post-surgical complications and scarring experienced after lesion removal. Also, specific anatomical location of lesions present cosmesis (i.e., face) or healing challenges (i.e., lower limbs). An effective injectable will benefit patients who are averse to surgery, at risk of wound healing complications or concerned with cosmesis outcomes or fatigued from multiple surgeries. Patient populations (i.e., elderly or patients with diabetes) who are at risk of delayed wound healing would benefit from an injectable option. This study will evaluate injection methods, interval of treatment, four ascending doses, safety, histological clearance and clinical clearance of biopsy-confirmed "low-risk" BCC lesion of \<20 mm located on non-facial skin.

03

Conditions studied

  • Superficial Basal Cell Carcinoma
  • Nodular Basal Cell Carcinoma
  • Nonmelanoma Skin Cancers

Browse trials for

Keywords

  • Nonmelanoma Skin Cancer
  • Keratinocyte Carcinoma
  • NMSC
  • BCC
  • basal cell carcinoma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, aged 18 to 80 years, inclusive
  2. No abnormalities identified by a detailed medical history and vital signs
  3. Presence of a confirmed low risk BCC lesion, with well-defined borders, and with a largest diameter measure before of 5 mm to 20 mm, located on arms or trunk
  4. Histological diagnosis of the target lesion must have been conducted 5 to 30 days prior to Day 1
  5. No other dermatological disease within 50 mm of the target lesion at Day 1
  6. No prior or concurrent treatment of the target lesion (including radiation therapy)
  7. Willing to undergo surgical excision approximately 63 days after first treatment.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of systemic cancer
  2. Prior radiation treatment at the lesion site or anywhere else on the body within the past 20 years
  3. Concurrent disease or treatment that suppresses the immune system (eg, previous organ transplant history, etc.)
  4. cardiovascular, endocrine, hepatic, neurologic, renal, or other major systemic disease that could complicate execution of the protocol or interpretation of the study results.
  5. History of thrombotic events, hemorrhagic events, and gastrointestinal perforation and fistula
  6. History of recurrence or presence of any other tumor subtype in the target lesion
  7. Concurrent presence of a malignant lesion within 100 mm of the target lesion that will require treatment during the study
  8. Current enrollment in any other drug or device study within 60 days of Day 1 of this study
  9. Evidence of dermatological disease or confounding dermatological condition that would hinder carrying out the study or interpreting the results (eg, atopic dermatitis, eczema, psoriasis, xeroderma pigmentosa, etc.)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    AIV001 Treatment Dose 1

    Intradermal/intratumoral, Dose 1

    Drug: AIV001 · Drug: AIV001 suspension

  • Experimental
    AIV001 Treatment Dose 2

    Intradermal/intratumoral, Dose 2

    Drug: AIV001 · Drug: AIV001 suspension

  • Experimental
    AIV001 Treatment Dose 3

    Intradermal/intratumoral, Dose 3

    Drug: AIV001 · Drug: AIV001 suspension

  • Experimental
    AIV001 Treatment Dose 4

    Intradermal/intratumoral, Dose 4

    Drug: AIV001 · Drug: AIV001 suspension

Interventions

06

What researchers measure

Primary outcomes

  1. Number of adverse events during study period

    Incidence of adverse events

    Time frame: Approximately 119 days

  2. Percentage of Histological Clearance achieved of BCC treated lesion

    full clearance is no residual BCC cells by histology

    Time frame: Cohort 1-3 Day 63; Cohort 4 Day 105 or Day 126

Secondary outcomes

  1. Percentage of Clinical Clearance of treated basal cell carcinoma lesion on skin surface

    Number of participants with no surface tumor visible in the study lesion on excision day

    Time frame: Cohort 1-3 Day 63; Cohort 4 Day 105 or Day 126

07

Study locations

4 sites
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • Island Dermatology
    Newport Beach, California 92660, United States
  • Skin Surgery Medical Group
    San Diego, California 92117, United States
  • Austin Institute for Clinical Research
    Pflugerville, Texas 78660, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Jun 2023, 34 months.

Of 28 phase 1 interventional studies under Carcinoma, Basal Cell, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 51. This study's 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2020
First posted
Jul 14, 2020
StartActual
Aug 18, 2020
Primary completionActual
Jun 20, 2023
CompletionActual
Jul 28, 2023
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Design
Removed Phase 2
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Design Removed Phase 2
    + 3 other changes: verification date, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04470726
Lead sponsor
AiViva BioPharma, Inc.
Responsible party
Sponsor
First posted
Jul 14, 2020
Start date
Aug 18, 2020
Primary completion
Jun 20, 2023
Completion
Jul 28, 2023
Last update
Nov 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Multi-kinase Inhbitor AIV001

Start the discussion